Pioneering Innovative Immunotherapy for Late-Stage Solid Tumor Cancers
COARE Holding Inc. is an OKC-based pre-clinical stage pharmaceutical company working to develop medications designed to treat late-stage and metastatic solid tumor cancers.
Metastatic cancers are by far the most prominent causes of mortality associated with nearly all solid tumor cancers. Colon, breast, ovarian, and pancreas are examples of tumors where safe and effective therapies that can prevent metastasis will fill a major unmet medical need.
Current standard therapies for these cancers contain highly toxic cocktails that often dramatically reduce the quality of life of patients with minimal improvement in patient survival. Moreover, many patients that experience effective initial response to therapy unfortunately develop resistance, experience tumor recurrence, and ultimately experience aggressive metastatic diseases. Usually, recur and experience metastasis due to the development of drug resistance.
COARE’s exciting new platform technology is directed towards eliminating the cancer cell populations responsible for tumor growth, metastasis, and resistance to most chemo, radio, and even the newer immunotherapies.
COARE's approach uses a novel cellular-based immunotherapy platform in combined with an anti-proliferative targeted strategy that utilizes a personalized medicine scheme to overcome resistance and prevent metastasis in patients with late-stage solid tumor cancers.
The fundamental focus of COARE’s anti-cancer therapeutic program is based on their identification of the novel master regulatory pro-tumorigenic protein Double Cortin-like Kinase 1 (DCLK1). DCLK1 is overexpressed in most solid tumor cancers and has been recently described as an exciting target for drug development.
The technology was developed in the Houchen Lab at the University of Oklahoma Health Sciences Center and is exclusively licensed to COARE Holdings Inc
COARE Holding Inc. is an OKC-based pre-clinical stage pharmaceutical company working to develop medications designed to treat late-stage and metastatic solid tumor cancers.
Metastatic cancers are by far the most prominent causes of mortality associated with nearly all solid tumor cancers. Colon, breast, ovarian, and pancreas are examples of tumors where safe and effective therapies that can prevent metastasis will fill a major unmet medical need.
Current standard therapies for these cancers contain highly toxic cocktails that often dramatically reduce the quality of life of patients with minimal improvement in patient survival. Moreover, many patients that experience effective initial response to therapy unfortunately develop resistance, experience tumor recurrence, and ultimately experience aggressive metastatic diseases. Usually, recur and experience metastasis due to the development of drug resistance.
COARE’s exciting new platform technology is directed towards eliminating the cancer cell populations responsible for tumor growth, metastasis, and resistance to most chemo, radio, and even the newer immunotherapies.
COARE's approach uses a novel cellular-based immunotherapy platform in combined with an anti-proliferative targeted strategy that utilizes a personalized medicine scheme to overcome resistance and prevent metastasis in patients with late-stage solid tumor cancers.
The fundamental focus of COARE’s anti-cancer therapeutic program is based on their identification of the novel master regulatory pro-tumorigenic protein Double Cortin-like Kinase 1 (DCLK1). DCLK1 is overexpressed in most solid tumor cancers and has been recently described as an exciting target for drug development.
The technology was developed in the Houchen Lab at the University of Oklahoma Health Sciences Center and is exclusively licensed to COARE Holdings Inc
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
